Association of Race, Substance Abuse, and Health Insurance Coverage With Use of Highly Active Antiretroviral Therapy Among HIV-Infected Women, 2005
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Stone, Valerie E.
Snow Jones, Alison
Golub, Elizabeth T.
Cohen, Mardge H.
Hessol, Nancy A.
Wilson, Tracey E.
Journal titleAmerican Journal of Public Health
Publication Begin page1493
Publication End page1499
MetadataShow full item record
AbstractObjectives: We examined racial/ethnic disparities in highly active antiretroviral therapy (HAART) use and whether differences are moderated by substance use or insurance status, using data from the Women's Interagency HIV Study (WIHS). Methods: Logistic regression examined HAART use in a longitudinal cohort of women for whom HAART was clinically indicated in 2005 (N = 1354). Results: Approximately 3 of every 10 eligible women reported not taking HAART. African American and Hispanic women were less likely than were White women to use HAART. After we adjusted for potential confounders, the higher likelihood of not using HAART persisted for African American but not for Hispanic women. Uninsured and privately insured women, regardless of race/ethnicity, were less likely than were Medicaid enrollees to use HAART. Although alcohol use was related to HAART nonuse, illicit drug use was not. Conclusions: These findings suggest that expanding and improving insurance coverage should increase access to antiretroviral therapy across racial/ethnic groups, but it is not likely to eliminate the disparity in use of HAART between African American and White women with HIV/AIDS.
CitationLillie-Blanton M, Stone VE, Snow Jones A, Levi J, Golub ET, Cohen MH, Hessol NA, Wilson TE. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health. 2010 Aug;100(8):1493-9. doi: 10.2105/AJPH.2008.158949. Epub 2009 Nov 12. PMID: 19910347; PMCID: PMC2901300.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity.
- Authors: McFall AM, Dowdy DW, Zelaya CE, Murphy K, Wilson TE, Young MA, Gandhi M, Cohen MH, Golub ET, Althoff KN, Women's Interagency HIV Study
- Issue date: 2013 Nov 1
- Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the U.S.
- Authors: Kahn JG, Zhang X, Cross LT, Palacio H, Birkhead GS, Morin SF
- Issue date: 2002 May-Jun
- Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States.
- Authors: Beer L, Mattson CL, Bradley H, Skarbinski J, Medical Monitoring Project
- Issue date: 2016 Mar
- The role of race and ethnicity in the State Children's Health Insurance Program (SCHIP) in four states: are there baseline disparities, and what do they mean for SCHIP?
- Authors: Shone LP, Dick AW, Brach C, Kimminau KS, LaClair BJ, Shenkman EA, Col JF, Schaffer VA, Mulvihill F, Szilagyi PG, Klein JD, VanLandeghem K, Bronstein J
- Issue date: 2003 Dec
- Race and insurance status as risk factors for trauma mortality.
- Authors: Haider AH, Chang DC, Efron DT, Haut ER, Crandall M, Cornwell EE 3rd
- Issue date: 2008 Oct